Evaluation of the Effects of L-carnitine Supplementation on Patients with COVID-19

Evaluation of the Effects of L-carnitine Supplementation on Clinical Outcomes in Hospitalized Patients with COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200921048794N1

Enrollment

Registered

2020-11-19

Start date

2021-02-19

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, Virus identified

Interventions

Intervention 1: Control group: This hospitalized group receives only their routine medication regimen which includes Dexamethasone, Interferon beta and Favipiravir. Intervention 2: Intervention group:

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 18 to 60 years Positive PCR Test Hospitalization Existence of Corona Virus Symptoms According to the Instructions of the Ministry of Health Mild to Moderate Disease Severity

Exclusion criteria

Exclusion criteria: Pregnancy Breastfeeding Severe Cardiovascular Disease HIV Infection History of Taking L-carnitine Supplementation in the Past Month Requires Care in the ICU Taking Anti-Inflammatory Drugs out of the Medication Regimen Patients with High and Critical Disease Severity Patient Dissatisfaction to Enter the Plan

Design outcomes

Primary

Measure	Time frame
C-Reactive Protein (CRP). Timepoint: At the Beginning of Intervention (the Zero day) and the End of Intervention (Fifth day ). Method of measurement: Blood test.;Erythrocyte Sedimentation Rate (ESR). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;O2 Saturation. Timepoint: Beginning and End of the Intervention. Method of measurement: Pulse Oximeter.;Complete Blood Count (CBC). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;White Blood Cell (WBC). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;Alanine Aminotransferase (ALT). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;Lactate Dehydrogenase (LDH). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;Creatine Phosphokinase (CPK). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;Creatinine. Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;Urea. Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;Prothrombin Time (PT). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;Red Cell Distribution Width (RDW). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.	—

Measure

Time frame

C-Reactive Protein (CRP). Timepoint: At the Beginning of Intervention (the Zero day) and the End of Intervention (Fifth day ). Method of measurement: Blood test.;Erythrocyte Sedimentation Rate (ESR). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;O2 Saturation. Timepoint: Beginning and End of the Intervention. Method of measurement: Pulse Oximeter.;Complete Blood Count (CBC). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;White Blood Cell (WBC). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;Alanine Aminotransferase (ALT). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;Lactate Dehydrogenase (LDH). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;Creatine Phosphokinase (CPK). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;Creatinine. Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;Urea. Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;Prothrombin Time (PT). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.;Red Cell Distribution Width (RDW). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test.

—

Secondary

Measure	Time frame
Fever. Timepoint: Beginning and End of the Intervention. Method of measurement: Patient File.;Cough. Timepoint: Beginning and End of the Intervention. Method of measurement: Questionnaire.;Mortality Rate. Timepoint: During the intervention. Method of measurement: Death of the Patient.;Duration of Hospitalization. Timepoint: Beginning and End of the Intervention. Method of measurement: Days.;ICU Referral. Timepoint: During the Intervention. Method of measurement: Observational.;Requires Ventilation. Timepoint: During the Intervention. Method of measurement: Observational.	—

Measure

Time frame

Fever. Timepoint: Beginning and End of the Intervention. Method of measurement: Patient File.;Cough. Timepoint: Beginning and End of the Intervention. Method of measurement: Questionnaire.;Mortality Rate. Timepoint: During the intervention. Method of measurement: Death of the Patient.;Duration of Hospitalization. Timepoint: Beginning and End of the Intervention. Method of measurement: Days.;ICU Referral. Timepoint: During the Intervention. Method of measurement: Observational.;Requires Ventilation. Timepoint: During the Intervention. Method of measurement: Observational.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehran Ghasemi

Hamedan University of Medical Sciences

mehranghasemy76@gmail.com+98 81 3838 1593

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026